René Beukema

Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands.

T.I.P. Europe Ltd. engaged in the operation of warehousing and storage facilities for land transport activities. The company was founded on March 26, 1986 and was headquartered in London, the United Kingdom.

GE Capital Europe Ltd. provides consumer financing services. It offers accounts receivable, financing, consumer, equipment and healthcare finance solutions. The firm provides industry specific expertise in aviation, energy, infrastructure, healthcare, and media to capitalize on market-specific opportunities. The company is headquartered in London, the United Kingdom.

Part of FedEx Corp., TNT Express Worldwide BV is a Dutch company that provides logistic and international mailing services. The company is based in Hoofddorp, Netherlands.

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector.

Vu Medical Center operates as a hospital.

Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom.